{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:24:18Z","timestamp":1784820258851,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T00:00:00Z","timestamp":1560297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Claudia Best and Nancy Wynserski"},{"name":"Shanghai BioEngine Sci-Tech"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.vaccine.2019.04.054","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T08:27:04Z","timestamp":1556526424000},"page":"7003-7010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Semi-perfusion cultures of suspension MDCK cells enable high cell concentrations and efficient influenza A virus production"],"prefix":"10.1016","volume":"37","author":[{"given":"Thomas","family":"Bissinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Fritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Mihut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2652-5943","authenticated-orcid":false,"given":"Yvonne","family":"Genzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Song","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Reichl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.04.054_b0005","unstructured":"World Health Organization. Up to 650 000 people die of respiratory diseases linked to seasonal flu each year; 2017. http:\/\/www.who.int\/en\/news-room\/detail\/14-12-2017-up-to-650-000-people-die-of-respiratory-diseases-linked-to-seasonal-flu-each-year\/ [accessed 12 December 2018]."},{"key":"10.1016\/j.vaccine.2019.04.054_b0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3201\/eid1209.05-0979","article-title":"1918 Influenza: the mother of all pandemics","volume":"12","author":"Taubenberger","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.054_b0015","doi-asserted-by":"crossref","first-page":"e66312","DOI":"10.1371\/journal.pone.0066312","article-title":"Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005\u20132011","volume":"8","author":"Kostova","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2019.04.054_b0020","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1016\/j.vaccine.2017.07.053","volume":"35","author":"Palache","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.054_b0025","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1586\/erv.11.82","article-title":"The future of cell culture-based influenza vaccine production","volume":"10","author":"Perdue","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.04.054_b0030","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1517\/14712598.4.5.709","article-title":"The role of cell culture vaccines in the control of the next influenza pandemic","volume":"4","author":"Audsley","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2019.04.054_b0035","first-page":"11","article-title":"Current and emerging cell culture manufacturing technologies for influenza vaccines","volume":"2015","author":"Ernest","year":"2015","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.vaccine.2019.04.054_b0040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41541-018-0079-z","article-title":"Cell culture-derived influenza vaccines in the severe 2017\u20132018 epidemic season: a step towards improved influenza vaccine effectiveness","volume":"3","author":"Barr","year":"2018","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2019.04.054_b0045","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1750-2659.2008.00053.x","article-title":"FluBlok, a recombinant hemagglutinin influenza vaccine","volume":"2","author":"Cox","year":"2008","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2019.04.054_b0050","series-title":"Approved products: flublock","author":"U.S. Food & Drug Administration","year":"2018"},{"key":"10.1016\/j.vaccine.2019.04.054_b0055","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1586\/erv.09.128","article-title":"Continuous cell lines as a production system for influenza vaccines","volume":"8","author":"Genzel","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.04.054_b0060","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1016\/S0264-410X(00)00508-9","article-title":"Mehtali M, Uytdehaag F. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines","volume":"19","author":"Pau","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.054_b0065","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00253-012-4238-2","article-title":"CAP, a new human suspension cell line for influenza virus production","volume":"97","author":"Genzel","year":"2013","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2019.04.054_b0070","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/infdis\/jiv091","article-title":"Immunogenicity and safety of an EB66 cell-culture-derived influenza A\/Indonesia\/5\/2005(H5N1) AS03-adjuvanted vaccine: a phase 1 randomized trial","volume":"212","author":"Schuind","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.054_b0075","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.1016\/j.vaccine.2013.09.051","article-title":"Comparison of influenza virus yields and apoptosis-induction in an adherent and a suspension MDCK cell line","volume":"31","author":"Peschel","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.054_b0080","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1016\/j.vaccine.2006.05.023","article-title":"Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media","volume":"24","author":"Genzel","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.054_b0085","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.1016\/j.vaccine.2008.08.015","article-title":"Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines","volume":"26","author":"Hu","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.054_b0090","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/btpr.262","article-title":"Growth behavior of number distributed adherent MDCK cells for optimization in microcarrier cultures","volume":"25","author":"Bock","year":"2009","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.vaccine.2019.04.054_b0095","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1016\/j.vaccine.2006.01.019","article-title":"Serum-free influenza virus production avoiding washing steps and medium exchange in large-scale microcarrier culture","volume":"24","author":"Genzel","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.054_b0100","first-page":"645","article-title":"Adherent and single-cell suspension culture of Madin-Darby canine kidney cells in serum-free medium","volume":"27","author":"Huang","year":"2011","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"key":"10.1016\/j.vaccine.2019.04.054_b0105","doi-asserted-by":"crossref","first-page":"14802","DOI":"10.1073\/pnas.0905912106","article-title":"Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production","volume":"106","author":"Chu","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2019.04.054_b0110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jviromet.2010.09.029","article-title":"Adaptation of a Madin-Darby canine kidney cell line to suspension growth in serum-free media and comparison of its ability to produce avian influenza virus to Vero and BHK21 cell lines","volume":"171","author":"van Wielink","year":"2011","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2019.04.054_b0115","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1016\/j.vaccine.2010.07.004","article-title":"A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor","volume":"28","author":"Lohr","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.054_b0120","unstructured":"Gr\u00f6ner A, Vorlop J; Chiron Behring Gmbh & Co. Processes for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process. European Patent Office, EP0891420B1. 1996 April 01."},{"key":"10.1016\/j.vaccine.2019.04.054_b0125","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1007\/s00705-017-3460-8","article-title":"Suspension culture process for H9N2 avian influenza virus (strain Re-2)","volume":"162","author":"Wang","year":"2017","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2019.04.054_b0130","doi-asserted-by":"crossref","first-page":"e0141686","DOI":"10.1371\/journal.pone.0141686","article-title":"Serum-Free Suspension Culture of MDCK Cells for Production of Influenza H1N1 Vaccines","volume":"10","author":"Huang","year":"2015","journal-title":"PloS one."},{"key":"10.1016\/j.vaccine.2019.04.054_b0135","series-title":"Animal cell culture","first-page":"407","article-title":"Perfusion processes","author":"Chotteau","year":"2015"},{"key":"10.1016\/j.vaccine.2019.04.054_b0140","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s00253-015-7267-9","article-title":"Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production","volume":"100","author":"Tapia","year":"2016","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2019.04.054_b0145","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.biotechadv.2018.04.011","article-title":"Perfusion mammalian cell culture for recombinant protein manufacturing \u2013 a critical review","volume":"36","author":"Bielser","year":"2018","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.vaccine.2019.04.054_b0150","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1472-6750-11-84","article-title":"Metabolic and Kinetic analyses of influenza production in perfusion HEK293 cell culture","volume":"11","author":"Petiot","year":"2011","journal-title":"BMC Biotech"},{"key":"10.1016\/j.vaccine.2019.04.054_b0155","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1016\/j.vaccine.2014.02.016","article-title":"High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells","volume":"32","author":"Genzel","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.054_b0160","doi-asserted-by":"crossref","first-page":"8725","DOI":"10.1007\/s00253-018-9275-z","article-title":"Process intensification of EB66\u00ae cell cultivations leads to high-yield yellow fever and Zika virus production","volume":"102","author":"Nikolay","year":"2018","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2019.04.054_b0165","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1016\/j.vaccine.2017.10.112","article-title":"High-cell-density cultivations to increase MVA virus production","volume":"36","author":"V\u00e1zquez-Ram\u00edrez","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.054_b0170","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1002\/jgm.503","article-title":"Development and optimization of an adenovirus production process","volume":"6","author":"Kamen","year":"2004","journal-title":"J Gene Med"},{"key":"10.1016\/j.vaccine.2019.04.054_b0175","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/bit.22364","article-title":"Cell density effect in the baculovirus-insect cells system: A quantitative analysis of energetic metabolism","volume":"104","author":"Bernal","year":"2009","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2019.04.054_b0180","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF00353919","article-title":"Engineering challenges in high density cell culture systems","volume":"22","author":"Ozturk","year":"1996","journal-title":"Cytotechnology"},{"key":"10.1016\/j.vaccine.2019.04.054_b0185","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.biologicals.2007.10.002","article-title":"Monitoring influenza virus content in vaccine production: Precise assays for the quantitation of hemagglutination and neuraminidase activity","volume":"36","author":"Kalbfuss","year":"2008","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2019.04.054_b0190","series-title":"Animal cell biotechnology: methods and protocols","first-page":"457","article-title":"Vaccine production","author":"Genzel","year":"2007"},{"key":"10.1016\/j.vaccine.2019.04.054_b0195","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1037\/h0063767","article-title":"Review of the method of 'Right and Wrong Cases' ('Constant Stimuli') without Gauss's formula","volume":"6","author":"Spearman","year":"1909","journal-title":"Psychol Bull"},{"key":"10.1016\/j.vaccine.2019.04.054_b0200","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01863914","article-title":"Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche","volume":"162","author":"K\u00e4rber","year":"1931","journal-title":"Naunyn-Schmiedebergs Archiv f\u00fcr experimentelle Pathologie und Pharmakologie"},{"key":"10.1016\/j.vaccine.2019.04.054_b0205","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1016\/j.vaccine.2015.02.077","article-title":"Monitoring changes in proteome during stepwise adaptation of a MDCK cell line from adherence to growth in suspension","volume":"33","author":"Kluge","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.054_b0210","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.biologicals.2010.04.003","article-title":"Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine","volume":"38","author":"Onions","year":"2010","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2019.04.054_b0215","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/fmb.10.161","article-title":"Safety of MDCK cell culture-based influenza vaccines","volume":"6","author":"Gregersen","year":"2011","journal-title":"Future Microbiol"},{"key":"10.1016\/j.vaccine.2019.04.054_b0220","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.1007\/s00253-015-6636-8","article-title":"Production of canine adenovirus type 2 in serum-free suspension cultures of MDCK cells","volume":"99","author":"Castro","year":"2015","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2019.04.054_b0225","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0042-6822(62)90182-4","article-title":"Inhibition by ammonium ion of the growth of influenza virus in chorioallantoic tissue","volume":"18","author":"Eaton","year":"1962","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.04.054_b0230","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/0042-6822(61)90149-0","article-title":"Inhibitory effect of glutamine and ammonia on replication of influenza virus in ascites tumor cells","volume":"13","author":"Eaton","year":"1961","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2019.04.054_b0235","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/BF01275221","article-title":"Ammonium chloride and viral penetration","volume":"20","author":"Eaton","year":"1967","journal-title":"Archiv f\u00fcr die gesamte Virusforschung"},{"key":"10.1016\/j.vaccine.2019.04.054_b0240","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.vaccine.2013.11.044","article-title":"Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor","volume":"32","author":"Tapia","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.054_b0245","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/bit.25459","article-title":"Characterization of apoptosis in PER.C6\u00ae batch and perfusion cultures","volume":"112","author":"Mercier","year":"2015","journal-title":"Biotechnol Bioeng"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19305286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19305286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:35:53Z","timestamp":1759401353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19305286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":49,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0264410X19305286"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.054","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Semi-perfusion cultures of suspension MDCK cells enable high cell concentrations and efficient influenza A virus production","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}